Clinical follow-up of paclitaxel-eluting (TAXUS™) stents for the treatment of saphenous vein graft disease

Journal of Interventional Cardiology

Volumn 20, Issue 4, 2007, Pages 258-264

  Ruchin, P E ^a   Faddy, S C ^a   Muller, D W M ^a   Baron, D W ^a   Roy, P R ^a   Wilson, S H ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; COURSE EVALUATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; NEW SOUTH WALES; PACLITAXEL; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SAPHENOUS VEIN; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547815110     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00268.x     Document Type: Article

References (27)

1. Boyle EM Jr., Lille ST, Allaire E, et al. Endothelial cell injury in cardiovascular surgery: Atherosclerosis. Ann Thorac Surg 1997 6 (3 Suppl. 885 894.
2. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991 34 (1 Suppl. 45 68.
3. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation 1998 97 (9 Suppl. 916 931.
4. Shah PJ, Gordon I, Fuller J, et al. Factors affecting saphenous vein graft patency: Clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg 2003 126 (6 Suppl. 1972 1977.
5. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996 28 (3 Suppl. 616 626.
6. Schmuziger M, Christenson JT, Maurice J, et al. Reoperative myocardial revascularization: An analysis of 458 reoperations and 2645 single operations. Cardiovasc Surg 1994 2 (5 Suppl. 623 629.
7. Yau TM, Borger MA, Weisel RD, et al. The changing pattern of reoperative coronary surgery: Trends in 1230 consecutive reoperations. J Thorac Cardiovasc Surg 2000 120 (1 Suppl. 156 163.
8. Savage MP, Douglas JS Jr., Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. New Engl J Med 1997 337 (11 Suppl. 740 747.
9. de Feyter PJ. Percutaneous treatment of saphenous vein bypass graft obstructions: A continuing obstinate problem. Circulation 2003 107 (18 Suppl. 2284 2286.
10. Holmes DR Jr., Topol EJ, Califf RM, et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. Circulation 1995 91 (7 Suppl. 1966 1974.
11. Lefkovits J, Holmes DR, Califf RM, et al. Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial. Circulation 1995 92 (4 Suppl. 734 740.
12. Baim DS, Wahr D, George B, et al. Saphenous vein graft angioplasty free of emboli randomized (SAFER) trial investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002 105 (11 Suppl. 1285 1290.
13. Stone GW, Rogers C, Hermiller J, et al. and the FilterWire EX Randomized Evaluation Investigators. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003 108 (5 Suppl. 548 553.
14. Schofer J, Schluter M, Gershlick AH, E-SIRIUS Investigators, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003 362 (9390 Suppl. 1093 1099.
15. Regar E, Serruys PW, Bode C, RAVEL Study Group, et al. Angiographic findings of the multicenter randomized study with the sirolimus-eluting Bx velocity balloon-expandable stent (RAVEL): Sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002 106 (15 Suppl. 1949 1956.
16. Schampaert E, Cohen EA, Schluter M, C-SIRIUS Investigators, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004 43 (6 Suppl. 1110 1115.
17. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003 107 (1 Suppl. 38 42.
18. Stone GW, Ellis SG, Cox DA, TAXUS-IV Investigators, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004 109 (16 Suppl. 1942 1947.
19. Stankovic G, Colombo A, Presbitero P. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: The randomized evaluation of polytetrafluoroethylene COVERed stent in saphenous vein grafts (RECOVERS) trial. Circulation 2003 108 : 37 42.
20. Tsuchida K, Ong AT, Aoki J, et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005 96 (3 Suppl. 395 398.
21. Hoye A, Lemos PA, Arampatzis CA, et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004 16 (5 Suppl. 230 233.
22. Price MJ, Sawhney N, Kao JA, et al. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interven 2005 65 (2 Suppl. 208 211.
23. Chu WW, Kuchulakanti PK, Wang B, et al. Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention. J Interven Cardiol 2006 19 (2 Suppl. 121 125.
24. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006 48 (12 Suppl. 2423 2431.
25. Wöhrle J, Nusser T, Kestler A, et al. Comparison of the slow-release polymerbased paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007 96 (2 Suppl. 70 76.
26. Ruchin PE, Faddy SC, Baron, et al. Use of sirolimus-eluting (CYPHER(tm)) stents in treatment of saphenous vein graft disease in an Australian population. Heart, Lung & Circulation 2004 13 : S27.
27. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005 45 (7 Suppl. 989 994.